Dr. Maria Eugenia Arcila, MD

Dr. Arcila practices at Memorial Pathology Group in New York, New York.

Dr. Arcila's NPI, 1760550594, was assigned on December 1, 2006. Dr. Arcila graduated from University of Pittsburgh School of Medicine in 1997. Dr. Arcila's Virginia license number on file is 0101221156.

Dr. Arcila's primary practice is Memorial Pathology Group, at 633 3rd Ave, New York, NY 10017 in New York County. The practice phone is (646) 227-3813.

Dr. Arcila's primary practice is Memorial Pathology Group in New York, New York. Dr. Arcila is also affiliated with Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Pathology Group. Dmand AI also links Dr. Arcila to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Arcila practices, 2 sites in all. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Arcila's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dr. Arcila is board certified in anatomic pathology & clinical pathology by the American Board of Pathology. Dmand AI has Dr. Arcila's licenses on file in 3 states: Virginia, New York and New Jersey.

CMS data shows 560 Medicare services from Dr. Arcila across 1 procedure code in 2024, for 477 Medicare patients. Medicare paid $22,096 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 477 Medicare patients who saw Dr. Arcila in 2024. The largest group is 65 to 74, with 224 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Arcila's median patient age at 69, with 50% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 77 out of 100 for Dr. Arcila for performance year 2024, reported as part of a group. Dr. Arcila accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 208 papers to Dr. Arcila, published from 2010 to 2025. 2020 was the busiest year, with 21. The most frequent topics are Lung Neoplasms, High-Throughput Nucleotide Sequencing and Biomarkers, Tumor. Dr. Arcila has published most often in Clin Cancer Res. Dr. Arcila's most frequent co-authors are Gregory J. Riely, MD, Mark G. Kris, MD and Charles M. Rudin, MD, PhD.

Dmand AI links Dr. Arcila to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoma, Follicular and Lymphoma, Non-Hodgkin.

CMS Open Payments shows 31 general payments to Dr. Arcila from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. AstraZeneca Pharmaceuticals LP paid the most, $26,971.

Dmand AI lists 1 award for Dr. Arcila, most recently Highly Cited Researcher in 2024.

Dr. Arcila graduated from University of Pittsburgh School of Medicine in 1997.

Dr. Arcila is in network with 4 carriers, including Excellus BlueCross BlueShield, MVP Health Care and CMS Medicare. EPO plans come from the most carriers, 2. Check the plan with the practice before a visit.